AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ODYSSEY THERAPEUTICS INC
US
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG0135WDLZ7
19.98▲ 0.91 (4.77%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
19.07
Day's Range
17.95 – 19.49
52-Week Range
15.35 – 20.30
Volume
1.6M
Avg Volume
471.4K
Share Statistics
Shares Outstanding
Employees
—
Exchange
US
Listed
—
Share count as of August 3, 2026

ODYSSEY THERAPEUTICS INC (ODTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about ODYSSEY THERAPEUTICS INC (ODTX)
What is ODYSSEY THERAPEUTICS INC's Market Cap?
ODYSSEY THERAPEUTICS INC's Market Cap is $960.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ODTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Change in fair value of contingent consideration
Total operating expenses
% of revenue——
Operating loss
% of revenue——
Other income (expense), net:
Interest income
Interest expense
Other expense, net
Total other income, net
Loss before income taxes
Income tax provision
Net loss
% of revenue——
Net loss attributable to common stockholders (see Note 15)
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted